ADC 3680B

Drug Profile

ADC 3680B

Alternative Names: ADC3680; ADC3680B; PTR-36

Latest Information Update: 04 Nov 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Pulmagen Therapeutics
  • Developer Pulmagen Therapeutics; Teijin
  • Class Antiasthmatics; Small molecules
  • Mechanism of Action Prostaglandin D2 receptor antagonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity Yes

Highest Development Phases

  • Phase II Allergic asthma; Asthma
  • No development reported Chronic obstructive pulmonary disease

Most Recent Events

  • 04 Nov 2017 No recent reports of development identified for phase-I development in Chronic-obstructive-pulmonary-disease(In volunteers) in United Kingdom (PO, Tablet)
  • 29 Jul 2015 Phase-II development is ongoing for Asthma in USA and Europe
  • 07 Dec 2014 Pulmagen Therapeutics completes a phase II trial in Asthma in USA, Croatia, Czech Republic, Germany, Hungary and Poland (NCT01730027)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top